Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Gene Modifying Immunotherapy for Blood Cancer Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Gene Modifying Immunotherapy for Blood Cancer Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 CAR T-cell Therapy
    • 1.4.3 TCR T-cell Therapy
  • 1.5 Market by Application
    • 1.5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Application: 2020 VS 2026
    • 1.5.2 Acute Lymphocytic Leukemia
    • 1.5.3 Chronic Lymphocytic Leukemia
    • 1.5.4 B Cell Lymphoma
    • 1.5.5 Multiple Myeloma
    • 1.5.6 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): Gene Modifying Immunotherapy for Blood Cancer Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Gene Modifying Immunotherapy for Blood Cancer Industry
      • 1.6.1.1 Gene Modifying Immunotherapy for Blood Cancer Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Gene Modifying Immunotherapy for Blood Cancer Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Gene Modifying Immunotherapy for Blood Cancer Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Gene Modifying Immunotherapy for Blood Cancer Market Perspective (2015-2026)
  • 2.2 Gene Modifying Immunotherapy for Blood Cancer Growth Trends by Regions
    • 2.2.1 Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Gene Modifying Immunotherapy for Blood Cancer Historic Market Share by Regions (2015-2020)
    • 2.2.3 Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Gene Modifying Immunotherapy for Blood Cancer Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Gene Modifying Immunotherapy for Blood Cancer Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Market Size
    • 3.1.1 Global Top Gene Modifying Immunotherapy for Blood Cancer Players by Revenue (2015-2020)
    • 3.1.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio
    • 3.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2019
  • 3.3 Gene Modifying Immunotherapy for Blood Cancer Key Players Head office and Area Served
  • 3.4 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
  • 3.5 Date of Enter into Gene Modifying Immunotherapy for Blood Cancer Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2015-2020)
  • 4.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2021-2026)

5 Gene Modifying Immunotherapy for Blood Cancer Breakdown Data by Application (2015-2026)

  • 5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
  • 5.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
  • 6.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in North America (2019-2020)
  • 6.3 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
  • 6.4 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
  • 7.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Europe (2019-2020)
  • 7.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
  • 7.4 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

8 China

  • 8.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
  • 8.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in China (2019-2020)
  • 8.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
  • 8.4 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
  • 9.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Japan (2019-2020)
  • 9.3 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
  • 9.4 Japan Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
  • 10.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

11 India

  • 11.1 India Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
  • 11.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in India (2019-2020)
  • 11.3 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
  • 11.4 India Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size (2015-2020)
  • 12.2 Gene Modifying Immunotherapy for Blood Cancer Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Type (2015-2020)
  • 12.4 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Novartis
    • 13.1.1 Novartis Company Details
    • 13.1.2 Novartis Business Overview and Its Total Revenue
    • 13.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.1.4 Novartis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020))
    • 13.1.5 Novartis Recent Development
  • 13.2 Kite Pharma
    • 13.2.1 Kite Pharma Company Details
    • 13.2.2 Kite Pharma Business Overview and Its Total Revenue
    • 13.2.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.2.4 Kite Pharma Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.2.5 Kite Pharma Recent Development
  • 13.3 Juno Therapeutics
    • 13.3.1 Juno Therapeutics Company Details
    • 13.3.2 Juno Therapeutics Business Overview and Its Total Revenue
    • 13.3.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.3.4 Juno Therapeutics Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.3.5 Juno Therapeutics Recent Development
  • 13.4 Cellectis
    • 13.4.1 Cellectis Company Details
    • 13.4.2 Cellectis Business Overview and Its Total Revenue
    • 13.4.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.4.4 Cellectis Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.4.5 Cellectis Recent Development
  • 13.5 Ziopharm Oncology
    • 13.5.1 Ziopharm Oncology Company Details
    • 13.5.2 Ziopharm Oncology Business Overview and Its Total Revenue
    • 13.5.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.5.4 Ziopharm Oncology Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.5.5 Ziopharm Oncology Recent Development
  • 13.6 Celyad
    • 13.6.1 Celyad Company Details
    • 13.6.2 Celyad Business Overview and Its Total Revenue
    • 13.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.6.4 Celyad Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.6.5 Celyad Recent Development
  • 13.7 Bluebird Bio
    • 13.7.1 Bluebird Bio Company Details
    • 13.7.2 Bluebird Bio Business Overview and Its Total Revenue
    • 13.7.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.7.4 Bluebird Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.7.5 Bluebird Bio Recent Development
  • 13.8 Bellicum Pharmaceuticals
    • 13.8.1 Bellicum Pharmaceuticals Company Details
    • 13.8.2 Bellicum Pharmaceuticals Business Overview and Its Total Revenue
    • 13.8.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.8.4 Bellicum Pharmaceuticals Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.8.5 Bellicum Pharmaceuticals Recent Development
  • 13.9 Mustang Bio
    • 13.9.1 Mustang Bio Company Details
    • 13.9.2 Mustang Bio Business Overview and Its Total Revenue
    • 13.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Introduction
    • 13.9.4 Mustang Bio Revenue in Gene Modifying Immunotherapy for Blood Cancer Business (2015-2020)
    • 13.9.5 Mustang Bio Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Novartis
    Kite Pharma
    Juno Therapeutics
    Cellectis
    Ziopharm Oncology
    Celyad
    Bluebird Bio
    Bellicum Pharmaceuticals
    Mustang Bio

    Market segment by Type, the product can be split into
    CAR T-cell Therapy
    TCR T-cell Therapy
    Market segment by Application, split into
    Acute Lymphocytic Leukemia
    Chronic Lymphocytic Leukemia
    B Cell Lymphoma
    Multiple Myeloma
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Gene Modifying Immunotherapy for Blood Cancer status, future forecast, growth opportunity, key market and key players.
    To present the Gene Modifying Immunotherapy for Blood Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Gene Modifying Immunotherapy for Blood Cancer are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now